Search results for "Raft"

showing 10 items of 1545 documents

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis

2013

Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under clean room conditions using CD45RA beads and analyzed LPs of six donors for cell composition and functional immune responses. CD45RA depletion resulted in 3.4-4.7 log (median 4.4) reduction of CD45RA(+) T cells, thereby eliminating naive and late effector T cells. B cells were also completely removed, whereas significant proportions of NK cells, monocytes and granulocytes persisted. CD45RA-depleted LPs contained effector and central memory CD4(+) a…

AdultCD4-Positive T-LymphocytesMaleHerpesvirus 4 HumanT-LymphocytesCytomegalovirusGraft vs Host DiseaseEnzyme-Linked Immunosorbent AssayCD8-Positive T-LymphocytesLymphocyte DepletionImmunophenotypingInterferon-gammaInterleukin 21ImmunophenotypingImmune systemAntigenAntigens NeoplasmHumansMedicineLeukapheresisCandidaTransplantationImmunomagnetic Separationbusiness.industryHematologyLeukapheresisFlow Cytometrymedicine.diseaseTransplantationAspergillusGraft-versus-host diseaseImmunologyLeukocyte Common AntigensbusinessCD8Bone Marrow Transplantation
researchProduct

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…

2014

Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…

AdultCancer ResearchPhases of clinical researchBreast NeoplasmsPharmacologyAntibodies Monoclonal HumanizedArticleReceptor IGF Type 1Ridaforolimuschemistry.chemical_compoundBreast cancerIn vivoAntineoplastic Combined Chemotherapy ProtocolsMedicineAnimalsHumansPI3K/AKT/mTOR pathwayInsulin-like growth factor 1 receptorAgedSirolimusDalotuzumabbusiness.industryTOR Serine-Threonine KinasesAntibodies MonoclonalReceptors SomatomedinMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysOncologychemistryMonoclonalbusinessSignal TransductionClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Increase of CCR7- CD45RA+ CD8 T cells (TEMRA) in Chronic Graft-versus-host Disease

2006

Among the late effects of hematopoietic stem cell transplantation (HSCT), chronic graft-vs-host disease (cGVHD) still remains as the major determinant of long-term outcome and quality of life. The disease typically appears between 3 months to 1.5 years following an allogeneic transplantation and is characterized by symptoms similar to those of autoimmune disease.

AdultCancer ResearchReceptors CCR7Allogeneic transplantationmedicine.medical_treatmentGraft vs Host DiseaseC-C chemokine receptor type 7DiseaseHematopoietic stem cell transplantationCD8-Positive T-LymphocytesCCR7 CD45RA CD8Quality of lifemedicineCytotoxic T cellHumansLymphocyte CountAutoimmune diseasebusiness.industryHematologymedicine.diseasesurgical procedures operativeGraft-versus-host diseaseOncologyImmunologyChronic DiseaseLeukocyte Common AntigensReceptors ChemokinebusinessImmunologic Memory
researchProduct

Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer pr…

2002

The objective of our study was to determine the effect of adding r-metHuSCF to Filgrastim and cyclophosphamide for mobilization of peripheral blood progenitor cells (PBPC), on collection of CD34(+) cells and engraftment after autologous stem cell transplant. Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m(2)), Filgrastim 5 microg/kg daily and r-metHuSCF 20 microg/kg daily. Two PBPC collections were performed on consecutive days starting the day the WBC count was above 7.5 x 10(3)/microl. Collection was performed between days +9 and +12 and the median number of CD34(+) cells collected was 9.9 x 10(6)/kg (1.1-53.1) and 6.6 x 10(6)/kg (1…

AdultCancer Researchmedicine.medical_specialtyFilgrastimPlatelet EngraftmentCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsFilgrastimTransplantation Autologouschemistry.chemical_compoundInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansNeoplasm MetastasisProgenitor cellCyclophosphamideAgedNeoplasm StagingStem Cell FactorChemotherapybusiness.industryHematologyMiddle AgedHematopoietic Stem CellsHematopoietic Stem Cell MobilizationRecombinant ProteinsNitrogen mustardGranulocyte colony-stimulating factorTransplantationTreatment OutcomeEndocrinologyOncologychemistryLymphatic MetastasisFemalebusinessStem Cell Transplantationmedicine.drugLeukemia
researchProduct

Antibodies to vascular endothelial cells in chronic rejection of renal allografts.

2000

AdultCytotoxicity ImmunologicGraft RejectionMalePathologymedicine.medical_specialtyTime FactorsAdolescentT-LymphocytesIsoantibodiesMedicineHumansTransplantation HomologousBlood TransfusionCells CulturedImmunosuppression TherapyTransplantationKidneyB-Lymphocytesbiologybusiness.industryHistocompatibility Antigens Class IMiddle AgedKidney TransplantationTransplantationEndothelial stem cellmedicine.anatomical_structureImmunologyHumoral immunityAntibody Formationbiology.proteinSurgeryFemaleEndothelium VascularAntibodybusinessBlood vesselFollow-Up StudiesTransplantation proceedings
researchProduct

Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease

2007

Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infections in recipients of hematopoietic stem cell transplants (HSCTs) who have graft-versus-host disease (GVHD). Design. Pharmacokinetic analysis in a subset of posaconazole-treated patients from a large, multicenter, phase III, randomized, double-blind, double-dummy, parallel-group trial that compared posaconazole with fluconazole. Setting. Ninety international medical centers. Patients. The subset of patients comprised 246 HSCT recipients for whom pharmacokinetic data were available. Intervention. All patients received posaconazole 200 mg oral suspension 3 times/day for a max…

AdultDiarrheaMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsAdolescentCmaxGraft vs Host DiseaseOpportunistic InfectionsGastroenterologySex FactorsDouble-Blind MethodPharmacokineticsOral administrationInternal medicinemedicineHumansTransplantation HomologousPharmacology (medical)MycosisAgedbusiness.industryBody WeightRacial GroupsAge FactorsHematopoietic Stem Cell TransplantationMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesAcute DiseaseChronic DiseaseFemalebusinessFluconazolemedicine.drugPharmacotherapy
researchProduct

Activity of the antiestrogenic cajanin stilbene acid towards breast cancer

2014

Antiestrogenic therapy is a mainstay for estrogen receptor (ERα)-positive breast cancer. Due to the development of resistance to established antihormones such as tamoxifen, novel compounds are required. The low abundant cajanin stilbene acid (CSA) recently isolated by us from Pigeon Pea (Cajanus cajan) has structural similarities with estrogen. We analyzed the cytotoxic and anticancer activity of CSA in ERα-positive and -negative human breast cancer cells in vitro, in vivo and in silico. CSA exerts anticancer and antiestrogenic activities towards ERα-positive breast cancer, and it showed cytotoxicity towards tamoxifen-resistant MCF-7 cells, implying that CSA may be active against tamoxifen-…

AdultEndocrinology Diabetes and MetabolismClinical BiochemistryMice NudeEstrogen receptorBreast NeoplasmsPharmacologyBiochemistryBreast cancerCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsStilbenesAnimalsHumansMedicineCytotoxic T cellPromoter Regions Geneticskin and connective tissue diseasesCytotoxicityMolecular BiologyNutrition and Dieteticsbusiness.industryEstrogen AntagonistsEstrogen Receptor alphaCancerMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysSalicylatesGene Expression Regulation NeoplasticTamoxifenReceptors EstrogenCancer cellMCF-7 CellsFemalebusinessEstrogen receptor alphaTamoxifenmedicine.drugThe Journal of Nutritional Biochemistry
researchProduct

16thIHIW: Anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates

2012

Summary In this multicentre study, sera from 803 retransplant candidates, including 775 kidney transplant recipients, were analysed with regard to the presence and specificity of anti-HLA alloantibodies of the IgA isotype using a modified microsphere-based platform. Of the kidney recipients, nearly one-third (n = 237, 31%) had IgA alloantibodies. Mostly, these antibodies were found in sera that also harboured IgG alloantibodies that could be found in a total of 572 (74%) of patients. Interestingly, IgA anti-HLA antibodies were preferentially targeting HLA class I antigens in contrast to those of the IgG isotype, which targeted mostly both HLA class I and II antigens. Donor specificity of th…

AdultGraft RejectionAdolescentImmunologyMedizinHuman leukocyte antigenMicrosphereAntigenAntibody SpecificityHLA AntigensIsoantibodiesGeneticsHumansMedicineIgg isotypeTypingChildMolecular BiologyGenetics (clinical)AgedAged 80 and overbiologybusiness.industryHistocompatibility TestingHistocompatibility Antigens Class IClass I AntigensInfantGeneral MedicineMiddle AgedKidney TransplantationVirologyIsotypeTissue DonorsAntibodies Anti-IdiotypicImmunoglobulin AChild PreschoolImmunoglobulin GImmunologybiology.proteinFemaleAntibodybusinessInternational Journal of Immunogenetics
researchProduct

Chemokines: reliable markers for diagnosis of rejection and inflammation following orthotopic liver transplantation.

2001

AdultGraft RejectionChemokinePathologymedicine.medical_specialtyOrthotopic liver transplantationAdolescentInflammationDiagnosis DifferentialPostoperative ComplicationsmedicineHumansReliability (statistics)AgedInflammationTransplantationbiologybusiness.industryMiddle AgedLiver TransplantationTransplantationChemokines CCCytomegalovirus Infectionsbiology.proteinSurgerymedicine.symptombusinessTransplantation proceedings
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct